Imperial Brands names new boss, sticks to guidance 08:01 , Graeme Evans Imperial Brands today ...

GSK Pharma reported a 35% rise in net profit to Rs 263 crore in Q4 FY25, while Aditya Birla Capital reported a net profit of ...

GSK Plc agreed to buy an experimental medicine to treat liver diseases for as much as $2 billion as the UK drugmaker seeks to ...

The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone ...

GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...

Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment optionsPhase II data show ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...